IPF Claims Another Victim (and Syndax's Stock Pays the Price)

The answer: no.

Axatilimab did not beat placebo on that primary endpoint. There's a small silver lining buried in the data: the drug's safety profile looked clean, with no new safety signals and no treatment-related deaths in either group. But in drug development, a safe drug that doesn't work is still a drug that doesn't work.

Syndax didn't hedge or promise a follow-up. The company said it does not plan further development in IPF, which is the clinical trial equivalent of unfollowing someone and blocking their number.

Welcome to the IPF Graveyard

If you're keeping score at home, axatilimab joins a long and distinguished list of IPF failures from the past several years. The graveyard includes:

• Ziritaxestat, an autotaxin inhibitor that flopped in Phase 3
• Zinpentraxin alfa (pentraxin-2), an anti-fibrotic protein that showed no benefit versus placebo in Phase 3
• Pamrevlumab, an anti-CTGF antibody that failed to improve lung function in Phase 3, killing its companion study in the process

The approved drugs that actually work in IPF — pirfenidone, nintedanib, and most recently nerandomilast (Jascayd) — slow progression but don't reverse scarring or cure the disease. Every attempt to do better has crashed and burned, regardless of the target or mechanism.

Researchers point to a cocktail of reasons: the biology is ferociously complex, patient populations are heterogeneous, and Phase 2 results often look better than they really are because studies are too small. Some experts also note that running trials on top of existing background therapy (most IPF patients already take pirfenidone or nintedanib) makes it even harder to detect a new drug's benefit. It's like trying to hear a whisper in a noisy restaurant.

The CSF-1R Thesis Takes a Hit

This failure has implications beyond Syndax. Axatilimab was the leading clinical program testing whether blocking CSF-1R could work in fibrotic lung disease.

The broader macrophage-targeting approach in fibrosis (including strategies like CCR2 antagonists) remains mostly preclinical or early-stage. So axatilimab's failure doesn't just close one door; it casts a shadow over an entire corridor of research. If the most advanced macrophage-directed therapy can't move the needle in IPF, the bar for the next attempt just got a lot higher.

What's Left for Syndax?

The good news for Syndax is that IPF was never the whole story. The company's two main pillars remain intact.

First, axatilimab's cGVHD franchise is alive and well. The drug is already approved for patients who've failed at least two prior therapies, and Syndax has two more cGVHD trials running. A Phase 2 study combining axatilimab with ruxolitinib in newly diagnosed cGVHD should deliver topline data in Q4 2026. A bigger Phase 3 trial pairing it with corticosteroids has data expected in early 2028. Syndax was clear that the IPF miss does not affect any of these programs.

Second, the company has revumenib, a selective menin inhibitor and an approved drug in its own right. Between a growing cGVHD label and a second commercial asset, Syndax has options, even if the IPF dream is dead.

But the 16% stock drop tells you something important: investors had priced in at least some IPF upside, and that evaporated in a single press release.

The Bigger Picture

IPF affects roughly 100,000 people in the U.S. alone, and available treatments are profoundly inadequate. The disease desperately needs new options. Yet the field keeps producing the same result: elegant science in the lab, disappointing data in the clinic.

Axatilimab's failure is a reminder that biology doesn't care about your mechanism-of-action slide deck. A drug can work beautifully in one fibrotic disease and completely whiff in another, because lungs are not skin, and IPF is not cGVHD. The immune system is a maze, and we keep running into the same walls.

Somewhere out there, another biotech is designing another IPF trial with another novel target. If history is any guide, the odds aren't in their favor. But somebody, eventually, has to crack it. The patients are running out of time, and the graveyard is running out of space.

The Bladder Cancer Drug That Just Got a Bigger Playground

The FDA just widened Anktiva's bladder cancer label to include high-grade papillary tumors, and it could reshape ImmunityBio's entire commercial story. Here's why a seemingly incremental regulatory update is actually a franchise-defining moment.